Cargando…

Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer

BACKGROUND: The purpose of this study was to investigate plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) and TAFI’s relationship with coagulation markers (prothrombin fragment 1 + 2) in gastric cancer patients. METHODS: Thirty-three patients with gastric adenocarcinoma and 29 hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Eser, Mehmet, Kement, Metin, Balin, Salim, Coskun, Cihan, Kefeli, Umut, Gumus, Mahmut, Altuntas, Yunus Emre, Kurt, Necmi, Mayadagli, Alparslan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502276/
https://www.ncbi.nlm.nih.gov/pubmed/22938027
http://dx.doi.org/10.1186/1477-7819-10-180
_version_ 1782250302681907200
author Eser, Mehmet
Kement, Metin
Balin, Salim
Coskun, Cihan
Kefeli, Umut
Gumus, Mahmut
Altuntas, Yunus Emre
Kurt, Necmi
Mayadagli, Alparslan
author_facet Eser, Mehmet
Kement, Metin
Balin, Salim
Coskun, Cihan
Kefeli, Umut
Gumus, Mahmut
Altuntas, Yunus Emre
Kurt, Necmi
Mayadagli, Alparslan
author_sort Eser, Mehmet
collection PubMed
description BACKGROUND: The purpose of this study was to investigate plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) and TAFI’s relationship with coagulation markers (prothrombin fragment 1 + 2) in gastric cancer patients. METHODS: Thirty-three patients with gastric adenocarcinoma and 29 healthy control subjects were prospectively enrolled in the study. Patients who had a history of secondary malignancy, thrombosis related disease, oral contraceptive use, diabetes mellitus, chronic renal failure or similar chronic metabolic disease were excluded from the study. A fasting blood sample was drawn from patients to determine the plasma levels of TAFI and Prothrombin Fragment 1 + 2 (F 1 + 2). In addition, data on patient age, sex, body mass index (BMI) and stage of disease were recorded. The same parameters, except stage of disease, were also recorded for the control group. Subsequently, we assessed the difference in the levels of TAFI and F 1 + 2 between the patient and control groups. Moreover, we investigated the relation of TAFI and F 1 + 2 levels with age, sex, BMI and stage of disease in the gastric cancer group. RESULTS: There were no statistical differences in any demographic variables (age, gender and BMI) between the groups (Table 1). The mean plasma TAFI levels of the gastric cancer group (69.4 ± 33.1) and control group (73.3 ± 27.5) were statistically similar (P = 0.62). The mean plasma F 1 + 2 level in the gastric cancer group was significantly higher than for those in the control group (549.7 ± 325.3 vs 151.9 ± 67.1, respectively; P < 0.001). In the gastric cancer group, none of the demographic variables (age, gender and BMI) were correlated with either TAFI or F 1 + 2 levels. Also, no significant associations were found between the stage of the cancer and either TAFI or F 1 + 2 levels. CONCLUSION: In our study, TAFI levels of gastric cancer patients were similar to healthy subjects. The results of our study suggest that TAFI does not play a role in pathogenesis of the hypercoagulable state in gastric cancer patients.
format Online
Article
Text
id pubmed-3502276
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35022762012-11-21 Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer Eser, Mehmet Kement, Metin Balin, Salim Coskun, Cihan Kefeli, Umut Gumus, Mahmut Altuntas, Yunus Emre Kurt, Necmi Mayadagli, Alparslan World J Surg Oncol Research BACKGROUND: The purpose of this study was to investigate plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) and TAFI’s relationship with coagulation markers (prothrombin fragment 1 + 2) in gastric cancer patients. METHODS: Thirty-three patients with gastric adenocarcinoma and 29 healthy control subjects were prospectively enrolled in the study. Patients who had a history of secondary malignancy, thrombosis related disease, oral contraceptive use, diabetes mellitus, chronic renal failure or similar chronic metabolic disease were excluded from the study. A fasting blood sample was drawn from patients to determine the plasma levels of TAFI and Prothrombin Fragment 1 + 2 (F 1 + 2). In addition, data on patient age, sex, body mass index (BMI) and stage of disease were recorded. The same parameters, except stage of disease, were also recorded for the control group. Subsequently, we assessed the difference in the levels of TAFI and F 1 + 2 between the patient and control groups. Moreover, we investigated the relation of TAFI and F 1 + 2 levels with age, sex, BMI and stage of disease in the gastric cancer group. RESULTS: There were no statistical differences in any demographic variables (age, gender and BMI) between the groups (Table 1). The mean plasma TAFI levels of the gastric cancer group (69.4 ± 33.1) and control group (73.3 ± 27.5) were statistically similar (P = 0.62). The mean plasma F 1 + 2 level in the gastric cancer group was significantly higher than for those in the control group (549.7 ± 325.3 vs 151.9 ± 67.1, respectively; P < 0.001). In the gastric cancer group, none of the demographic variables (age, gender and BMI) were correlated with either TAFI or F 1 + 2 levels. Also, no significant associations were found between the stage of the cancer and either TAFI or F 1 + 2 levels. CONCLUSION: In our study, TAFI levels of gastric cancer patients were similar to healthy subjects. The results of our study suggest that TAFI does not play a role in pathogenesis of the hypercoagulable state in gastric cancer patients. BioMed Central 2012-08-31 /pmc/articles/PMC3502276/ /pubmed/22938027 http://dx.doi.org/10.1186/1477-7819-10-180 Text en Copyright ©2012 Eser et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Eser, Mehmet
Kement, Metin
Balin, Salim
Coskun, Cihan
Kefeli, Umut
Gumus, Mahmut
Altuntas, Yunus Emre
Kurt, Necmi
Mayadagli, Alparslan
Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
title Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
title_full Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
title_fullStr Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
title_full_unstemmed Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
title_short Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
title_sort is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502276/
https://www.ncbi.nlm.nih.gov/pubmed/22938027
http://dx.doi.org/10.1186/1477-7819-10-180
work_keys_str_mv AT esermehmet isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer
AT kementmetin isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer
AT balinsalim isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer
AT coskuncihan isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer
AT kefeliumut isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer
AT gumusmahmut isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer
AT altuntasyunusemre isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer
AT kurtnecmi isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer
AT mayadaglialparslan isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer